全国住院患者样本2012—2018年镰状细胞病妊娠人群的严重孕产妇并发症与死亡
该横断面研究为美国全国住院患者样本(覆盖20%急性住院)的二次分析,纳入2012—2018年11—55岁分娩住院5 401 899例,其中镰状细胞病3901例、黑人742 164例。镰状细胞病组孕产妇死亡率13.3/万(95% CI 5.7-31.2),约为非黑人对照0.5/万(95% CI 0.5-0.6)的26倍、黑人非镰状细胞病组1.2/万(95% CI 1.0-1.5)的10倍以上。镰状细胞病分娩的严重孕产妇并发症校正比值比7.22(95% CI 6.25-8.34,P<.001),脑血管事件22.00、血栓栓塞17.34。种族差异中位解释镰状细胞病相关超额风险的28.9%,作者呼吁在科学、临床与政策层面努力改善结局。
要点
- 镰状细胞病分娩孕产妇死亡率13.3/万(95% CI 5.7-31.2),是非黑人对照0.5/万的26倍、黑人非镰状细胞病1.2/万的10倍以上。
- 镰状细胞病分娩严重孕产妇并发症校正比值比7.22(95% CI 6.25-8.34,P<.001),脑血管事件aOR 22.00(P<.001)、血栓栓塞aOR 17.34(P<.001)。
- 种族差异中位解释镰状细胞病分娩超额风险的28.9%(IQR 21.2%-33.1%),急性肾衰竭超额风险56.9%、宫内胎死47.8%、子痫42.1%中40%-50%归因于种族差异。
- 镰状细胞病组与黑人组均更年轻(平均27.2岁、27.1岁 vs 28.7岁),公共保险比例更高(67.3%、65.4% vs 40.8%)。
- 作者认为需科学、临床与政策层面努力改善镰状细胞病妊娠者结局。
适用人群与场景
- 美国全国住院患者样本中2012—2018年11—55岁分娩住院者,包括镰状细胞病3901例分娩、黑人742 164例分娩及非黑人对照人群。
- 数据来自覆盖美国20%急性住院的全国住院患者样本,属住院分娩场景。
诊断标准与关键阈值
- 严重孕产妇并发症采用美国疾病控制与预防中心(CDC)指数定义。
红旗征与不能漏的情况
- 镰状细胞病分娩者脑血管事件风险显著升高(aOR 22.00,95% CI 15.25-31.72,P<.001)。
- 镰状细胞病分娩者血栓栓塞风险显著升高(aOR 17.34,95% CI 11.55-26.03,P<.001)。
- 镰状细胞病分娩者孕产妇死亡率13.3/万(95% CI 5.7-31.2),需警惕死亡风险。
研究设计与关键结果
- 研究类型为横断面研究,系全国住院患者样本的二次分析,纳入2012—2018年5 401 899例分娩(镰状细胞病3901例、黑人742 164例)。
- 与非黑人对照组相比,镰状细胞病组与黑人组更年轻(平均[SD]年龄:镰状细胞病27.2[5.9]岁、黑人27.1[6.1]岁 vs 28.7[5.9]岁),公共保险比例更高(镰状细胞病2609例分娩[67.3%]、黑人496 828例分娩[65.4%] vs 1 880 198例分娩[40.8%])。
- 每10 000例分娩孕产妇死亡率:镰状细胞病13.3(95% CI 5.7-31.2),黑人1.2(95% CI 1.0-1.5),非黑人对照0.5(95% CI 0.5-0.6);镰状细胞病约为非黑人对照的26倍、黑人非镰状细胞病的10倍以上。
- 与非黑人对照相比,镰状细胞病分娩严重孕产妇并发症校正比值比7.22(95% CI 6.25-8.34,P<.001),脑血管事件aOR 22.00(95% CI 15.25-31.72,P<.001),血栓栓塞aOR 17.34(95% CI 11.55-26.03,P<.001)。
- 种族差异中位解释镰状细胞病分娩超额风险的28.9%(IQR 21.2%-33.1%),并解释急性肾衰竭超额风险56.9%(95% CI 54.3%-59.3%)、宫内胎死47.8%(95% CI 46.6%-49.1%)、子痫42.1%(95% CI 37.9%-46.1%)中40%-50%的超额风险。
证据类型、等级与局限
- 证据类型为横断面研究,系全国住院患者样本的二次分析,数据收集于2012—2018年,分析于2021年9月至2022年8月。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,本研究发现促使科学、临床与政策层面努力改善镰状细胞病妊娠者结局。
- 对镰状细胞病分娩者,需关注血栓栓塞与脑血管事件风险升高(aOR分别为17.34与22.00)及孕产妇死亡风险(13.3/万)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Pregnancy outcomes are historically poor among people with sickle cell disease (SCD) in the US, most of whom have Black race. Whether outcomes have improved is unknown.
OBJECTIVE: To tabulate adverse pregnancy outcomes among patients with SCD, comparing outcomes of deliveries among Black people with SCD with those of Black people without SCD and a control non-Black population, and to measure the association of racial disparities with adverse outcomes in SCD pregnancies.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was a secondary analysis involving data from National Inpatient Sample, a nationally representative sample of 20% of acute hospital admissions in the US, between 2012 and 2018. The data set included all admissions with codes for delivery of a pregnancy among people aged 11 to 55 years. Data were analyzed from September 2021 to August 2022.
EXPOSURES: SCD, racial disparities.
MAIN OUTCOMES AND MEASURES: Severe maternal morbidity (SMM) as measured by the US Centers for Disease Control and Prevention's index alongside other outcomes; multiple logistic regression was used to compare the odds for adverse pregnancy outcomes.
RESULTS: The sample included 5 401 899 deliveries, including 3901 deliveries among people with SCD and 742 164 deliveries among people with Black race. Compared with the non-Black control group, patients with SCD and Black patients were younger (mean [SD] age: SCD, 27.2 [5.9] years; Black, 27.1 [6.1] years vs 28.7 [5.9] years) and more likely to have public insurance (SCD, 2609 deliveries [67.3%]; Black, 496 828 deliveries [65.4%] vs 1 880 198 deliveries [40.8%]). The maternal mortality rate in deliveries among people with SCD was 26 times greater than in the non-Black control group and more than 10 times greater than among Black pregnant people without SCD (Per 10 000 deliveries: SCD 13.3; 95% CI, 5.7-31.2; Black race, 1.2; 95% CI, 1.0-1.5; non-Black control 0.5; 95% CI, 0.5-0.6). Compared with the control group, SCD deliveries had higher odds of SMM (adjusted odds ratio [aOR], 7.22; 95% CI, 6.25-8.34; P < .001), especially cerebrovascular events (aOR, 22.00; 95% CI, 15.25-31.72; P < .001) and thromboembolism (aOR, 17.34; 95% CI, 11.55-26.03; P < .001). Racial disparities explained a median (IQR) 28.9% (21.2%-33.1%) of the increased risk in deliveries to people with SCD and between 40% and 50% of the increased risk for acute kidney failure (excess risk [ER], 56.9%; 95% CI, 54.3%-59.3%), intrauterine fetal demise (ER, 47.8%; 95% CI, 46.6%-49.1%), and eclampsia (ER, 42.1%; 95% CI, 37.9%-46.1%).
CONCLUSIONS AND RELEVANCE: In this large cross-sectional study of pregnancy outcomes in people with SCD, the risk for SMM was higher compared with deliveries among people without SCD, especially for thrombotic events, organ failure, and death. Racial disparities were associated with adverse outcomes. Our findings compel scientific, clinical, and political effort to improve outcomes for pregnant people with SCD.
参考来源
- Early ML, Eke AC, Gemmill A, et al. Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018. JAMA Netw Open. 2023. PMID: 36729452. doi:10.1001/jamanetworkopen.2022.54552
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。